Medical Device News Magazine

BioMech, ēlizur Announce Partnership Integrating AI-enabled Motion Analytics into Physical Therapy Solution

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

BioMech Health, a division of BioMech Holdings, LLC, and ēlizur, a leading musculoskeletal solutions provider, announced today a groundbreaking agreement to integrate BioMech Lab™ Into the Shoulder Strengthening and Stabilization System (SSS).

The national partnership brings together two industry leading mechanical and digital solutions to create an in-home product capable of quantifying rehabilitative outcomes while increasing patient adherence to and engagement with physician-directed physical therapy protocols.

“Coupling the SSS advanced mechanical technology and BioMech Lab’s cutting-edge motion analytics is the perfect union to deliver enhanced therapeutic decision support for improved patient compliance with prescribed physical therapy protocols. It also provides the quantifiable outcomes needed to confirm the reliability of the SSS device,” said BioMech Founder Frank Fornari, Ph.D.

BioMech Lab™ delivers to clinicians the real-time functional motion metrics needed to rapidly evaluate, design, and monitor physical, surgical, pharmaco, and cognitive therapies. Using advanced sensor technology, powerful artificial intelligence (AI) and machine learning (ML) algorithms, and interactive biofeedback, BioMech Lab captures motion data in clinical and real-world settings and delivers precise, accurate, and reproducible assessments and treatment modifications that stratify risk and improve care outcomes.

“SSS has helped more than 4,000 patients accelerate rehabilitation from injury or surgery while reducing the number of required outpatient sessions. Adding BioMech Lab’s powerful analytics and biofeedback capabilities creates an even more robust system that can now deliver the actionable information needed to maximize outcomes while lowering costs,” said ēlizur President Jim Grant.

The SSS is designed for early-stage in-home rehabilitation use in the interim between discharge and outpatient therapy. A complement to outpatient rehabilitation, SSS offers a convenient, cost-effective alternative for patients who are not yet ready for, or do not have easy access to outpatient rehabilitation centers. ēlizur virtual clinical specialists – physical therapists, athletic trainers and orthopedic nurses depending upon the patient’s specific need – support the patient with set up and compliant use of the SSS device based on the physician-prescribed therapeutic protocol.

Says Fornari: “The BioMech Lab-SSS combination leverages automation to transform an integral but subjective assessment process and delivers quantifiable metrics to measure progress and validate effectiveness of therapeutic protocols.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”